Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Rheum Dis. 2017 Oct;24(5):293-302. English. Meta-Analysis. https://doi.org/10.4078/jrd.2017.24.5.293
Kim D , Cho SK , Nam SW , Kwon HH , Jung SY , Jeon CH , Im SG , Kim D , Jang EJ , Sung YK .
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. sungyk@hanyang.ac.kr
College of Pharmacy, Chung-Ang University, Seoul, Korea.
Division of Rheumatology, Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Bucheon, Korea.
Department of Statistics, Kyungpook National University, Daegu, Korea.
Department of Information Statistics, Andong National University, Andong, Korea.
Abstract

Objective

To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs).

Methods

A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics.

Results

From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59 compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18) during the 12 week period. For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration.

Conclusion

Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA.

Copyright © 2019. Korean Association of Medical Journal Editors.